• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Germany Geographic Atrophy (GA) Market

    ID: MRFR/HC/49910-HCR
    200 Pages
    Garvit Vyas
    September 2025

    Germany Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) andBy Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Germany Geographic Atrophy (GA) Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Germany Geographic Atrophy (GA) Market Summary

    The Germany Geographic Atrophy market is poised for substantial growth, projected to reach 5.5 USD billion by 2035.

    Key Market Trends & Highlights

    Germany Geographic Atrophy GA Key Trends and Highlights

    • The market valuation for Geographic Atrophy in Germany is estimated at 1.94 USD billion in 2024.
    • By 2035, the market is expected to expand to 5.5 USD billion, indicating a robust growth trajectory.
    • The compound annual growth rate (CAGR) from 2025 to 2035 is projected at 9.94%, reflecting increasing demand.
    • Growing adoption of innovative treatment options due to rising prevalence of age-related macular degeneration is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.94 (USD Billion)
    2035 Market Size 5.5 (USD Billion)
    CAGR (2025-2035) 9.94%

    Major Players

    Santen Pharmaceutical, Greenlight Biosciences, Astellas Pharma, Ophthotech, Kymab, Novartis, Applied Genetic Technologies Corporation, Luminex Corporation, Bayer, Hawkeye Therapeutics, Roche, Amgen, Pfizer, Regeneron Pharmaceuticals, Aerie Pharmaceuticals

    Germany Geographic Atrophy (GA) Market Trends

    The Germany Geographic Atrophy (GA) market is currently experiencing significant trends driven by the increasing prevalence of age-related macular degeneration (AMD) in the aging population. With advances in diagnostic technologies, more individuals are being identified with GA at earlier stages, allowing for better management and treatment options. Improved awareness and education campaigns among healthcare providers and patients about the impact of GA further contribute to an increasing demand for innovative therapies. The German healthcare system is emphasizing patient-centric approaches, ensuring that treatment pathways are tailored to individual needs and maximizing patient outcomes.

    There are ample opportunities to be explored in the German GA market, particularly in the realm of gene therapies and new drug development. Research institutions in Germany are making strides in identifying potential genetic markers and therapeutic targets for GA. Collaborations between pharmaceutical companies and research universities are on the rise, fostering an environment that encourages innovation in treatment modalities. Additionally, the regulatory framework in Germany is supportive of fast-tracking new treatments, which can help bring novel solutions to market more efficiently.

    In recent times, there has been a noticeable increase in investment in telemedicine solutions for monitoring GA patients.This is especially relevant as digital health initiatives in Germany are promoted by the government, aligning with the increasing need for remote patient monitoring solutions, especially following the pandemic. Furthermore, the trend towards personalized medicine is becoming prominent, as healthcare professionals aim to provide tailored treatment strategies based on individual patient profiles. With the solid foundation of research and patient care services in Germany, the GA market is set to undergo continuous evolution, adapting to meet the needs of a growing patient population.

    Germany Geographic Atrophy (GA) Market Drivers

    Market Segment Insights

    Geographic Atrophy GA Market Age Group Insights

    The Age Group segment within the Germany Geographic Atrophy GA Market reflects a critical aspect of the landscape of age-related visual impairments, particularly as the population continues to age. Germany has one of the highest life expectancies in the world, leading to a significant proportion of its population being above 60 years. This age group is particularly vulnerable to geographic atrophy due to the natural deterioration of retinal cells that is often associated with aging.

    As people live longer, maintaining quality of life is increasingly recognized as a crucial public health issue, driving the demand for effective treatments and interventions for age-related conditions, including geographic atrophy. The age group above 75 years holds substantial importance within this market, as this demographic often faces a higher incidence of severe eye-related disorders, including geographic atrophy.

    This age group represents a significant challenge for healthcare systems due to the high prevalence of comorbidities often found in older populations. As life expectancy increases, so does the need for timely and effective solutions to enhance visual health and overall well-being. With advancements in technology and treatment options, there are growing opportunities for innovation in managing geographic atrophy, making it essential for stakeholders to focus on this demographic.

    The increasing patient base within these age groups fuels the market growth, as health policies and research funding continue to target aging populations. In addition, the demographic shift indicates that healthcare practices and market strategies must be adapted to accommodate the needs of older adults. As the population over 60 and 75 continues to grow, emphasis on accessibility and effective treatment channels becomes paramount.

    Furthermore, healthcare providers in Germany have been recognizing the need for comprehensive care strategies that address not only the medical aspects of geographic atrophy but also the social and psychological impacts on the aging population. As healthcare dynamics evolve, understanding the intricacies of the Age Group segment can contribute significantly to devising tailored solutions that can drive the provision of care and support for aging individuals facing geographic atrophy-related challenges.

    Geographic Atrophy GA Market Diagnosis Insights

    The Diagnosis segment of the Germany Geographic Atrophy GA Market plays a crucial role in the detection and monitoring of this progressive eye condition. With the increasing prevalence of age-related macular degeneration in Germany, innovative diagnostic techniques are becoming essential. Fundus Autofluorescence stands out as a vital tool, enabling clinicians to visualize retinal pigment changes associated with geographic atrophy. Optical Coherence Tomography Angiography is another significant advancement, offering non-invasive imaging that provides detailed vascular information, allowing for early intervention. Multifocal Electroretinography contributes by assessing retinal function, thereby helping in the comprehensive evaluation of patients.

    Together, these technologies support timely and accurate diagnosis, which is imperative for effective management strategies. As the Germany Geographic Atrophy GA Market continues to evolve, the emphasis on advanced diagnostic methods is expected to grow, driven by technological advancements and increasing awareness among healthcare professionals. Moreover, with Germany's robust healthcare system, investments in Research and Development are likely to spur innovations in this segment, further enhancing the Germany Geographic Atrophy GA Market's landscape.

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights

    The Therapeutic Agents Clinical Phase segment within the Germany Geographic Atrophy GA Market is characterized by its significant role in developing treatments for geographic atrophy, a leading cause of vision loss. The market is experiencing notable growth, driven by the increasing prevalence of age-related macular degeneration among the aging population in Germany. Late-stage development candidates are crucial as they represent the final step before potential market approval, contributing to the urgency of effective, innovative therapies.

    Meanwhile, Phase II and Phase I stages focus on refining dosage and assessing efficacy and safety, respectively, aiding in the rapid advancement of viable treatment options. The Pre-Clinical Stage and Discovery Candidates lay the groundwork for future breakthroughs, with ongoing research in novel therapeutic approaches. This segment is essential for fostering innovation in the industry and addressing the unmet medical needs of patients suffering from geographic atrophy, reflecting the commitment within Germany's robust healthcare ecosystem to combat vision-threatening diseases.

    Overall, a disciplined focus on each developmental phase ensures that the market is optimally positioned to deliver effective therapeutic agents, ultimately improving patient outcomes.

    Get more detailed insights about Germany Geographic Atrophy (GA) Market

    Request Free Sample

    Regional Insights

    Key Companies in the Germany Geographic Atrophy (GA) Market market include

    Industry Developments

    Recent developments in the Geographic Atrophy market in Germany indicate a growing interest from major pharmaceutical companies such as Novartis and Bayer, focusing on innovative solutions for retinal degenerative diseases. In July 2023, Astellas Pharma and Hawkeye Therapeutics announced a collaboration to advance the development of therapies targeting Geographic Atrophy, which reflects a trend towards strategic partnerships in this field. Additionally, Santen Pharmaceutical has made significant advancements in Research and Development, aiming to launch new treatment modalities by 2024.

    Financially, the market valuation for companies like Roche and Amgen has seen a notable increase due to heightened investments in clinical trials and emerging therapies for geographic atrophy. Furthermore, the ongoing discussions around potential mergers and acquisitions within the sector are closely monitored, with a keen interest in the activity between Ophthotech and Kymab. In the past two years, the German market witnessed a surge in awareness and emphasis on Geographic Atrophy, leading to increased collaborative efforts among stakeholders and impactful advancements aimed at improving patient outcomes, establishing Germany as a pivotal region in treating this condition.

    Market Segmentation

    Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates

    Geographic Atrophy GA Market Age Group Outlook

    • Above 60 Years
    • Above 75 Years

    Geographic Atrophy GA Market Diagnosis Outlook

    • Fundus Autofluorescence
    • Optical Coherence Tomography Angiography
    • Multifocal Electroretinography

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.94(USD Billion)
    MARKET SIZE 2024 2.5(USD Billion)
    MARKET SIZE 2035 5.5(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 7.431% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Santen Pharmaceutical, Greenlight Biosciences, Astellas Pharma, Ophthotech, Kymab, Novartis, Applied Genetic Technologies Corporation, Luminex Corporation, Bayer, Hawkeye Therapeutics, Roche, Amgen, Pfizer, Regeneron Pharmaceuticals, Aerie Pharmaceuticals
    SEGMENTS COVERED Age Group, Diagnosis, Therapeutic Agents Clinical Phase
    KEY MARKET OPPORTUNITIES Aging population increase, Growing awareness and screening, Advancements in gene therapy, Innovative treatment options development, Collaborations with healthcare providers
    KEY MARKET DYNAMICS rising elderly population, increasing prevalence of GA, advancements in treatment options, growing awareness and diagnosis, strong research and development initiatives
    COUNTRIES COVERED Germany

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the Germany Geographic Atrophy GA Market in 2024?

    The Germany Geographic Atrophy GA Market is expected to be valued at 2.5 billion USD in 2024.

    What is the projected market value for the Germany Geographic Atrophy GA Market by 2035?

    By 2035, the overall market value for Germany Geographic Atrophy GA Market is anticipated to reach 5.5 billion USD.

    What is the expected compound annual growth rate (CAGR) for the Germany Geographic Atrophy GA Market from 2025 to 2035?

    The CAGR for the Germany Geographic Atrophy GA Market is expected to be 7.431% from 2025 to 2035.

    Which age groups are specifically targeted in the Germany Geographic Atrophy GA Market?

    The market is divided by age groups, particularly focusing on individuals above 60 years and above 75 years.

    What is the market size for the Germany Geographic Atrophy GA Market for individuals above 60 years in 2024?

    The market size for individuals above 60 years is expected to be 1.5 billion USD in 2024.

    What is the projected market size for individuals above 75 years in the Germany Geographic Atrophy GA Market by 2035?

    The market size for individuals above 75 years is expected to reach 2.0 billion USD by 2035.

    Who are the key players in the Germany Geographic Atrophy GA Market?

    Major players include Santen Pharmaceutical, Astellas Pharma, Novartis, and Regeneron Pharmaceuticals among others.

    What opportunities exist in the Germany Geographic Atrophy GA Market during the forecast period?

    There are significant opportunities for growth driven by an increasing aging population and advancements in treatment options.

    How does the Germany Geographic Atrophy GA Market grow with respect to current trends?

    The market is expected to grow due to rising awareness, a growing patient base, and enhanced therapeutic innovations.

    What challenges could affect the growth of the Germany Geographic Atrophy GA Market?

    Challenges could include regulatory hurdles and the need for comprehensive clinical trials for new therapies.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. Germany Geographic Atrophy GA Market, BY Age Group (USD Billion)
    45. Above 60 Years
    46. Above 75 Years
    47. Germany Geographic Atrophy GA Market, BY Diagnosis (USD Billion)
    48. Fundus Autofluorescence
    49. Optical Coherence Tomography Angiography
    50. Multifocal Electroretinography
    51. Germany Geographic Atrophy GA Market, BY Therapeutic Agents Clinical Phase (USD Billion)
    52. Late-Stage
    53. Phase II
    54. Phase I
    55. Pre-Clinical Stage
    56. Discovery Candidates
    57. Competitive Landscape
    58. Overview
    59. Competitive Analysis
    60. Market share Analysis
    61. Major Growth Strategy in the Geographic Atrophy GA Market
    62. Competitive Benchmarking
    63. Leading Players in Terms of Number of Developments in the Geographic Atrophy GA Market
    64. Key developments and growth strategies
    65. New Product Launch/Service Deployment
    66. Merger & Acquisitions
    67. Joint Ventures
    68. Major Players Financial Matrix
    69. Sales and Operating Income
    70. Major Players R&D Expenditure. 2023
    71. Company Profiles
    72. Santen Pharmaceutical
    73. Financial Overview
    74. Products Offered
    75. Key Developments
    76. SWOT Analysis
    77. Key Strategies
    78. Greenlight Biosciences
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Astellas Pharma
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Ophthotech
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Kymab
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Novartis
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Applied Genetic Technologies Corporation
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Luminex Corporation
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Bayer
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Hawkeye Therapeutics
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Roche
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Amgen
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. Pfizer
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Regeneron Pharmaceuticals
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Aerie Pharmaceuticals
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. Germany Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD Billions)
    165. Germany Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2035 (USD Billions)
    166. Germany Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019-2035 (USD Billions)
    167. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    168. ACQUISITION/PARTNERSHIP
    169. MARKET SYNOPSIS
    170. GERMANY GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY AGE GROUP
    171. GERMANY GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY DIAGNOSIS
    172. GERMANY GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY THERAPEUTIC AGENTS CLINICAL PHASE
    173. KEY BUYING CRITERIA OF GEOGRAPHIC ATROPHY GA MARKET
    174. RESEARCH PROCESS OF MRFR
    175. DRO ANALYSIS OF GEOGRAPHIC ATROPHY GA MARKET
    176. DRIVERS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    177. RESTRAINTS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    178. SUPPLY / VALUE CHAIN: GEOGRAPHIC ATROPHY GA MARKET
    179. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2025 (% SHARE)
    180. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2019 TO 2035 (USD Billions)
    181. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2025 (% SHARE)
    182. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2019 TO 2035 (USD Billions)
    183. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2025 (% SHARE)
    184. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019 TO 2035 (USD Billions)
    185. BENCHMARKING OF MAJOR COMPETITORS

    Germany Geographic Atrophy GA Market Segmentation

     

    • Geographic Atrophy GA Market By Age Group (USD Billion, 2019-2035)

      • Above 60 Years
      • Above 75 Years

     

    • Geographic Atrophy GA Market By Diagnosis (USD Billion, 2019-2035)

      • Fundus Autofluorescence
      • Optical Coherence Tomography Angiography
      • Multifocal Electroretinography

     

    • Geographic Atrophy GA Market By Therapeutic Agents Clinical Phase (USD Billion, 2019-2035)

      • Late-Stage
      • Phase II
      • Phase I
      • Pre-Clinical Stage
      • Discovery Candidates

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027